Rhythm raises $25M in Series B financing for diabetes and obesity

Thursday, June 14, 2012 09:14 AM

Rhythm, a biotech based in Boston, Mass., has raised $25 million in a Series B financing round, bringing the total capital raised to $65 million.

Rhythm will use the proceeds to continue advancing its small-peptide therapeutics for metabolic diseases through phase II clinical trials. RM-131 is a ghrelin agonist currently in phase II study for the treatment of diabetic gastroparesis. RM-493, an agonist of the melanocortin 4 receptor (MC4R), is currently in phase II trials for the treatment of obesity and diabetes.

"We have made great progress since we started both development programs in 2010, and this could only have been achieved with a strong and dedicated investor syndicate," said Bart Henderson, founder and president of Rhythm. "These programs have great potential for addressing major unmet needs in diabetes, obesity and gastrointestinal functional disorders, and this financing supports a broad and thorough phase II development program for both drugs."

All existing investors participated in the round — MPM Capital, New Enterprise Associates and Third Rock Ventures — as well as new investor, Ipsen.

"We see the potential for transforming the treatment of diabetes and other metabolic diseases with molecules that activate the ghrelin and MC4R pathways with high potency and specificity,” said Lou Tartaglia, PhD, partner at Third Rock Ventures. “We are pleased to invest in Rhythm and to be working with a great management team as it moves this exciting portfolio of peptides forward."

In connection with the financing, Vaughn Kailian, managing director of MPM Capital, was added to Rhythm's board of directors. He joins board members Tartaglia; Keith Gottesdiener, MD, CEO of Rhythm; Ed Mathers, a partner at NEA; and Christian de la Tour, chairman of Ipsen U.K. Companies.

Share:          
CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs